FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for STIVARGA (regorafenib) to expand its indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Unresectable Gastrointestinal Stromal Tumor
• Unresectable Hepatocellular Carcinoma

Drugs mentioned

• Stivarga (regorafenib)

Snippet

SUPPL AP for STIVARGA (REGORAFENIB)